Brokerages Set GSK plc (NYSE:GSK) PT at $43.25

GSK plc (NYSE:GSK) has been assigned a consensus rating of “Moderate Buy” from the nine research firms that are currently covering the company, Marketbeat Ratings reports. Six equities research analysts have rated the stock with a hold recommendation and three have given a strong buy recommendation to the company. The average 12 month price objective among brokerages that have covered the stock in the last year is $43.25.

GSK has been the topic of several research analyst reports. Guggenheim cut shares of GSK from a “buy” rating to a “neutral” rating in a report on Thursday, October 31st. StockNews.com cut GSK from a “strong-buy” rating to a “buy” rating in a report on Tuesday, January 21st. Deutsche Bank Aktiengesellschaft lowered GSK from a “buy” rating to a “hold” rating in a report on Friday, November 15th. Finally, Jefferies Financial Group downgraded GSK from a “buy” rating to a “hold” rating and dropped their target price for the stock from $53.00 to $39.50 in a report on Tuesday, November 12th.

Hedge Funds Weigh In On GSK

A number of hedge funds have recently added to or reduced their stakes in the stock. FMR LLC grew its holdings in shares of GSK by 8.3% during the 3rd quarter. FMR LLC now owns 29,008,928 shares of the pharmaceutical company’s stock worth $1,185,885,000 after purchasing an additional 2,224,345 shares in the last quarter. Fisher Asset Management LLC lifted its position in GSK by 1.4% during the fourth quarter. Fisher Asset Management LLC now owns 18,836,797 shares of the pharmaceutical company’s stock worth $637,061,000 after purchasing an additional 259,867 shares during the period. Primecap Management Co. CA grew its stake in GSK by 2.4% during the third quarter. Primecap Management Co. CA now owns 14,853,755 shares of the pharmaceutical company’s stock worth $607,222,000 after buying an additional 342,365 shares in the last quarter. Equity Investment Corp increased its holdings in GSK by 13.3% in the 4th quarter. Equity Investment Corp now owns 3,962,581 shares of the pharmaceutical company’s stock valued at $134,014,000 after buying an additional 466,327 shares during the period. Finally, Provident Trust Co. raised its position in shares of GSK by 1.7% in the 3rd quarter. Provident Trust Co. now owns 3,953,602 shares of the pharmaceutical company’s stock valued at $161,623,000 after buying an additional 66,765 shares in the last quarter. Institutional investors own 15.74% of the company’s stock.

GSK Stock Up 8.1 %

GSK stock opened at $37.67 on Friday. GSK has a 1-year low of $31.72 and a 1-year high of $45.92. The business’s 50 day simple moving average is $34.10 and its 200 day simple moving average is $37.60. The company has a current ratio of 0.81, a quick ratio of 0.53 and a debt-to-equity ratio of 0.98. The firm has a market capitalization of $78.07 billion, a PE ratio of 24.46, a PEG ratio of 1.38 and a beta of 0.64.

GSK (NYSE:GSK) last released its quarterly earnings data on Wednesday, February 5th. The pharmaceutical company reported $0.59 EPS for the quarter, beating the consensus estimate of $0.44 by $0.15. GSK had a net margin of 7.97% and a return on equity of 50.62%. As a group, research analysts anticipate that GSK will post 3.92 EPS for the current year.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.